Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Begins Controversial 12 Week Strategy With AZ and Pfizer Vaccines

US Won’t Follow, But Germany And Denmark Might

Executive Summary

Entering a new lockdown, the UK sees its plans to space out doses of the COVID-19 vaccines to 12 weeks as crucial to overcoming the pandemic.

You may also be interested in...



COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data

The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.

Coronavirus Update: Pfizer CEO Thinks Vaccine Price Rise Likely Post-Pandemic

Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.

Coronavirus Notebook: EU Opinion On Moderna’s mRNA-1273 Expected This Week, UK Boosts Vaccine Rollout As Lockdown Imposed

UK biotech firm Emergex has signed a deal with Brazil’s Biocruz for the development of a T-cell based vaccine, and the Philippines regulator has issued a warning after reports that members of the country’s presidential guard received an unauthorized vaccine produced by China’s Sinopharm.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel